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Prevalence of HCV by Occult HBV status
Conclusion: Though the overall prevalence of occult HBV
(7%) in our community clinic is lower than historical preva-
lence of 11%, among those not on ARV the prevelance was
much higher (22%). Further, high proportion of patients with
isolated anti HBc also tested positive for HCV ab (47.4%).
Therefore clinicians should have a high index of suspicion
for occult HBV among HIV infected patients whose hepati-
tis panel is positive only for core antibody.Clinicians should
have a high index of suspicion for occult HBV among HIV
infected patients whose hepatitis panel is positive only for
core antibody particularly those not on ARV and with HCV
coinfection.
doi:10.1016/j.ijid.2010.02.515
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Predictors for hepatic carcinoma surveillance screening
in a cohort of hepatitis B and HIV coinfected patients in a
large urban HIV clinic
A. Adejumo1,∗, Z. Oshikanlu2, V. Sivapalan1
1 Columbia University College Of Physicians and Surgeons
afﬁliation at Harlem Hospital Center, New York, NY, USA
2 Columbia University College of Physicians and Surgeons
afﬁliation at Harlem Hospital, New York, NY, USA
Background: Co-infection with hepatitis B virus (HBV) and
HIV is common. Approximately 70-90% of HIV-infected indi-
viduals have evidence of past or active infection with HBV.
It is unclear what predicts the likelihood that patient with
active HBV/HIV infection will receive appropriate surveil-
lance screening for hepatic carcinoma. We hypothesized
that patients who have successful HIV treatment are likely to
have successful hepatic carcinoma surveillance screening.
Methods: To evaluate predictors for surveillance screen-
ing of hepatic carcinoma within the period of July 2008
to June 2009. A retrospective review of medical records
of patients with active HBV and HIV co-infection for hep-
atic ultrasound, alpha fetoprotein (AFP), liver biopsy, HBV
viral load, HBV e Ag screenings and gastroenterologist (GI)
referral.
Results: Of 77 HIV infected patients whose charts were
randomly selected, 55.8% (n =43) obtained care during the
study period. The demographic was 58% male (n=25). 7 of 43
patients (n =16.3%) had active HBV infection. All 7 patients
were referred for hepatic ultrasound, only 43% (n =3) had
the procedure performed with 66% (n =2) abnormal. All 7
patients had AFP screening, hepatitis B DNA measurement,
hepatitis B e Ag screening and GI referral. 1of 7 patients had
an elevated AFP while all 7 had detectable HBV DNA and 43%
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n =3) had positive hepatitis B e antigen. 71% (n =5) had an
nitial GI evaluation while only 28% (n =2) had >1 GI follow
p. 28% (n =2) were no show. None of the 7 patients had liver
iopsy.
In patients who did not obtain an abdominal ultrasound or
ho did not follow up with GI or no show, there was no signif-
cant difference in the CD4 count range when compared to
hose who obtained ultrasound or follow with GI. 57% (n =4)
f patients had issues with adherence as documented in the
hart. All 4 patients did not obtain abdominal ultrasound, 3
id not follow up with GI and 1 was no show.
Conclusion: 16.3% of our cohort of HBV/HIV co-infected
atients had active HBV infection. Non-adherence to fol-
ow up plan is the reason in patients who did not obtain
bdominal ultrasound or GI evaluation. CD4 count did not
ppear to be a predictor of probability to obtain hepatic car-
inoma screening. Strategies that improve adherence will
ikely improve the success of hepatic carcinoma surveillance
creening.
oi:10.1016/j.ijid.2010.02.516
8.011
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Background: Tenofovir (TDF) is a nucleotide with dual
ctivity against HIV and hepatitis B (HBV) viruses. Thus, it
as become the antiviral of choice for HIV-HBV co-infected
atients when treatment for both viral infections is indi-
ated.
Methods: We reviewed 19 medical records of patients
ho received tenofovir as part of the antiviral treatment.
ive patients had previously received 3TC (lamivudine) as
art of HAART. Immunological parameters were recorded for
IV infection (CD4/mm3), AST, ALT and viral loads for HIV
nd HBV were followed over an average period of 27 months
range, 3-44m).
Results: All patients were male and the median age was
2 years (range, 29-65). Concomitant antiviral medications
ere 1 NRTI +1 NNRTI (3TC/FTC) in 13 patients, 1 ritonavir-
oosted PI + 1 NNRTI in 1 patient, 1 PI + 1 NRTI (3TC or
TC) in 4 patients and 1 IP ritonavir-boosted + 2NRTI (AZT +
TC) in 1 patient. The mean HBV DNA at baseline was: 6.53
og. Six patients presented at baseline with normal ALT and
3 a mean elevation of AST/ALT x 3,8/x 5. The results of
iver biopsy were available for 6 patients: 1 had cirrhosis,
mild chronic hepatitis (stage 1), 2 moderate chronic hep-
titis (stage 2). 17 patients were HBeAg positive, and two
ere HBeAg negative at baseline. Seven out of 17 patients
e th In
u
H
a
H
t
w
h
l
4
6
t
T
r
p
d
7
A
b
H
A
a
a
m
i
p
c
i
h
t
a
h
t
2
m
i
l
H
a
t
l
(
4
t
t
p
3
a
p
T
a
a
t
i
m
H
h
i
t
H
d
7
C
i
A
M
A
p
s
a
o
c
H
c
C
t
a
d
(
2
f
M
S
n
1
1
N
(
w
(
L
t
s
e
o
m
y
s404 14
nderwent HBeAg loss and seroconversion to anti e. Loss of
BsAg was documented in 1 patient. HBV-DNA follow up was
vailable in 17/19 patients (2/19 pending). 13/17 achieved
BV-DNA undetectability (mean 58 weeks). 4/17 reduced
heir HBV-DNA by a mean of 4.75 log (range: 3.1 to 6.2 log)
ith a mean follow up of 33 weeks. Among 13 patients who
ad abnormal ALT at baseline, 9 normalized during the fol-
ow up. Among patients previously experienced with 3TC:
achieved undetectable HBV DNA and the other decreased
.2 log from baseline.
Conclusion: As pointed out by the international litera-
ure, we found a high virological and biochemical efﬁcacy of
DF in HIV-HBV co-infected patients, in terms of HBV antivi-
al inhibition in both previously treated with 3TC and naive
atients.
oi:10.1016/j.ijid.2010.02.517
8.012
n assessment of the seroprevalence of hepatitis A anti-
ody and vaccination among HIV patients in an inner city
IV clinic
. Adejumo ∗, V. Sivapalan, S. Mannheimer
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Background: Routine hepatitis A virus (HAV) screening
nd vaccination is recommended in the guidelines for the
anagement of high risk persons infected with the human
mmunodeﬁciency virus (HIV). Scientiﬁc evidence shows that
atients with no immunity against HAV suffer prolonged
linical course and hepatitis related liver abnormalities if
nfected with acute hepatitis when compared to those who
ave immunity. The objective of this study is to assess
he seroprevalence of anti-HAV and hepatitis A vaccination
mong high risk patients in the outpatient HIV clinic.
Methods: A retrospective review of medical records of
igh risk adult patients (age > 18y) who attended the outpa-
ient HIV clinic between the period of July 2007 - December
008. The clinic provides primary care services to approxi-
ately 750 HIV-infected patients. The clinic demographics
nclude 47% women, 83% Blacks and 14% Latinos.
Results: 244 high risk HIV infected adult patients had at
east one visit within the study period. All received anti-
AV screening, of which 87.3% (n=213) tested negative for
nti-HAV and 12.7% (n=31) tested positive. Among those who
ested negative, 12% (n=26) had only 1 visit and did not fol-
ow up. Of the remaining 187 patients who followed up, 60%
n=113) received at least 1 dose of hepatitis A vaccine and
0% (n=74) did not receive a single dose of vaccine. Among
he total 244 patients, 18 had perinatally acquired HIV infec-
ion. 88% (n=16) of these patients with perinatal HIV had
ositive anti-HAV and are responsible for 52% of the total
1 patients with positive antibody. All the 31 patients with
nti-HAV had more than 1 visit.
Conclusion: In our cohort of high risk HIV infected adults,
atients with perinatal HIV are more likely to have anti-HAV.
he seroprevalence of anti-HAV in our chort is low (12.7%)
nd similar to the rate reported in other studies. The hep-
titis A vaccination rate of 60% in our cohort is below the
arget of greater than 90% vaccination rate needed for herd
a
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mmunity to lessen the impact of the disease in the com-
unity. The high rate of anti-HAV in patients with perinatal
IV highlights the effectiveness of the strategy for child-
ood hepatitis A vaccination schedule. Comparable success
n adult patients will require a higher adherence to vaccina-
ion recommendations in order to prevent HAV infection in
IV patients.
oi:10.1016/j.ijid.2010.02.518
8.013
entral nervous system opportunistic infections (CNS-OI)
n HIV-infected children from Buenos Aires, Argentina
. Fallo ∗, A. de Mena, L. Torrado, N. Sordelli, G.
anonelles, E.L. Lopez
Hospital de Nin˜os ‘‘Ricardo Gutiérrez’’, Buenos Aires,
rgentina
Background: CNS-OI is a frequent event in adult AIDS
atients (pts) with decreasing rates in the HAART era. The
pectrum of CNS disease is quite different in paediatric AIDS
nd there are very few reports about the incidence rates
f CNS-OI in children. The objective was to describe the
linical course and outcome risk of CNS-OI in a perinatally
IV-infected cohort from Argentina.
Methods: Retrospective study among 397 HIV infected
hildren followed-up from 1998-2008. All pts with conﬁrmed
NS-OI infection were included. Pts with congenital infec-
ions, other neurological disorders or without an etiologic
gent identiﬁed were excluded.
Results: Out of 397 pts, 23 (6%) developed 24 CNS OI
uring follow-up (0.8/100 personyears). Bacterial meningitis
BM) 6 (25%), which were N meningitidis 2, St. pneumoniae
, St. agalactiae 1 and L monocytogenes 1. TB 5 (21%), C neo-
ormans (Crypto) 4 (17%), toxoplasmosis 2 (8%), JCV 2 (8%),
AI 1 (4%), CMV 1 (4%), EBV-CNS lymphoma 1(4%), measles
SPE 1 (4%). Common initial symptoms were fever (61%),
eurological deﬁcits (26%) and headache (22%).
At diagnosis of OI, mean age: 7.6 ± 6 years, mean CD4:
5 ± 14%, mean viral load: 4.8 ± 1 log.
CNS OI was the ﬁrst manifestation of HIV in 6 pts (26%);
7 were on HAART, 11 of them (48%) had poor adherence.
o IRIS was assumed.
BM and TB were more prevalent in the youngest pts
median age: 5 vs 12 years. p=0.03). Median CD4% of BM
as higher than the rest (30 vs 5 p=0.007)
Neurological sequelaes were present in 6. Six pts died
26%). Causes of death were 1 TB, 1 MAI, 1 JCV, 1 EBV-
ymphoma, 1 CMV and 1 Crypto. CNS-OI mortality was higher
han in the rest of pts, 6/23 vs 31/374 (p=0.01) and KM
urvival log rank p=0.03.
Conclusion: In developing countries OI are still prevalent,
specially in pts with late diagnosis of HIV, poor adherence
r advanced AIDS disease. In this series, a signiﬁcant high
ortality was observed. BM and TB were more prevalent in
ounger children. In older children, the spectrum was more
imilar to adults and the relation with low CD4 was more
ccurate.
oi:10.1016/j.ijid.2010.02.519
